vs
Side-by-side financial comparison of Pediatrix Medical Group, Inc. (MD) and Westrock Coffee Co (WEST). Click either name above to swap in a different company.
Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $339.5M, roughly 1.5× Westrock Coffee Co). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs -6.6%, a 13.5% gap on every dollar of revenue. On growth, Westrock Coffee Co posted the faster year-over-year revenue change (48.3% vs -1.7%). Over the past eight quarters, Westrock Coffee Co's revenue compounded faster (32.8% CAGR vs -0.1%).
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
Westrock Coffee Co is a global integrated coffee, tea and functional beverage solutions provider. It sources, roasts, manufactures and distributes coffee products, ready-to-drink beverages and custom formulations for retail, foodservice and commercial clients across North America and other key markets.
MD vs WEST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $493.8M | $339.5M |
| Net Profit | $33.7M | $-22.6M |
| Gross Margin | — | 11.5% |
| Operating Margin | 9.9% | -2.6% |
| Net Margin | 6.8% | -6.6% |
| Revenue YoY | -1.7% | 48.3% |
| Net Profit YoY | 10.5% | 8.3% |
| EPS (diluted) | $0.40 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $493.8M | $339.5M | ||
| Q3 25 | $492.9M | $354.8M | ||
| Q2 25 | $468.8M | $280.9M | ||
| Q1 25 | $458.4M | $213.8M | ||
| Q4 24 | $502.4M | $229.0M | ||
| Q3 24 | $511.2M | $220.9M | ||
| Q2 24 | $504.3M | $208.4M | ||
| Q1 24 | $495.1M | $192.5M |
| Q4 25 | $33.7M | $-22.6M | ||
| Q3 25 | $71.7M | $-19.1M | ||
| Q2 25 | $39.3M | $-21.6M | ||
| Q1 25 | $20.7M | $-27.2M | ||
| Q4 24 | $30.5M | $-24.6M | ||
| Q3 24 | $19.4M | $-14.3M | ||
| Q2 24 | $-153.0M | $-17.8M | ||
| Q1 24 | $4.0M | $-23.7M |
| Q4 25 | — | 11.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 14.7% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 16.8% | ||
| Q2 24 | — | 19.9% | ||
| Q1 24 | — | 19.4% |
| Q4 25 | 9.9% | -2.6% | ||
| Q3 25 | 13.8% | -2.4% | ||
| Q2 25 | 12.8% | -5.3% | ||
| Q1 25 | 7.0% | -6.1% | ||
| Q4 24 | 7.8% | -4.3% | ||
| Q3 24 | 6.6% | -5.8% | ||
| Q2 24 | -31.3% | -7.9% | ||
| Q1 24 | 3.2% | -5.3% |
| Q4 25 | 6.8% | -6.6% | ||
| Q3 25 | 14.5% | -5.4% | ||
| Q2 25 | 8.4% | -7.7% | ||
| Q1 25 | 4.5% | -12.7% | ||
| Q4 24 | 6.1% | -10.7% | ||
| Q3 24 | 3.8% | -6.5% | ||
| Q2 24 | -30.3% | -8.5% | ||
| Q1 24 | 0.8% | -12.3% |
| Q4 25 | $0.40 | $-0.22 | ||
| Q3 25 | $0.84 | $-0.20 | ||
| Q2 25 | $0.46 | $-0.23 | ||
| Q1 25 | $0.24 | $-0.29 | ||
| Q4 24 | $0.37 | $-0.26 | ||
| Q3 24 | $0.23 | $-0.16 | ||
| Q2 24 | $-1.84 | $-0.20 | ||
| Q1 24 | $0.05 | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $375.2M | $49.9M |
| Total DebtLower is stronger | $570.5M | $444.1M |
| Stockholders' EquityBook value | $865.9M | $-1.9M |
| Total Assets | $2.2B | $1.2B |
| Debt / EquityLower = less leverage | 0.66× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $375.2M | $49.9M | ||
| Q3 25 | $340.1M | $34.0M | ||
| Q2 25 | $224.7M | $44.0M | ||
| Q1 25 | $99.0M | $33.1M | ||
| Q4 24 | $229.9M | $26.2M | ||
| Q3 24 | $103.8M | $22.4M | ||
| Q2 24 | $19.4M | $24.3M | ||
| Q1 24 | $8.0M | $12.6M |
| Q4 25 | $570.5M | $444.1M | ||
| Q3 25 | $577.2M | — | ||
| Q2 25 | $583.9M | — | ||
| Q1 25 | $590.5M | — | ||
| Q4 24 | $597.1M | $393.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $865.9M | $-1.9M | ||
| Q3 25 | $890.7M | $11.4M | ||
| Q2 25 | $833.8M | $18.2M | ||
| Q1 25 | $789.2M | $71.4M | ||
| Q4 24 | $764.9M | $97.5M | ||
| Q3 24 | $732.5M | $110.3M | ||
| Q2 24 | $706.5M | $81.5M | ||
| Q1 24 | $856.2M | $91.7M |
| Q4 25 | $2.2B | $1.2B | ||
| Q3 25 | $2.2B | $1.2B | ||
| Q2 25 | $2.1B | $1.2B | ||
| Q1 25 | $2.0B | $1.1B | ||
| Q4 24 | $2.2B | $1.1B | ||
| Q3 24 | $2.1B | $1.1B | ||
| Q2 24 | $2.0B | $1.1B | ||
| Q1 24 | $2.2B | $983.3M |
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 0.78× | 4.03× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $114.1M | $36.7M |
| Free Cash FlowOCF − Capex | — | $27.8M |
| FCF MarginFCF / Revenue | — | 8.2% |
| Capex IntensityCapex / Revenue | — | 2.6% |
| Cash ConversionOCF / Net Profit | 3.39× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-107.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $114.1M | $36.7M | ||
| Q3 25 | $137.3M | $-26.6M | ||
| Q2 25 | $137.2M | $-7.0M | ||
| Q1 25 | $-117.5M | $-22.1M | ||
| Q4 24 | $133.0M | $2.8M | ||
| Q3 24 | $91.8M | $-332.0K | ||
| Q2 24 | $107.0M | $-23.7M | ||
| Q1 24 | $-125.2M | $8.0M |
| Q4 25 | — | $27.8M | ||
| Q3 25 | — | $-44.7M | ||
| Q2 25 | — | $-27.5M | ||
| Q1 25 | — | $-63.4M | ||
| Q4 24 | — | $-15.4M | ||
| Q3 24 | — | $-36.7M | ||
| Q2 24 | — | $-59.9M | ||
| Q1 24 | — | $-60.9M |
| Q4 25 | — | 8.2% | ||
| Q3 25 | — | -12.6% | ||
| Q2 25 | — | -9.8% | ||
| Q1 25 | — | -29.7% | ||
| Q4 24 | — | -6.7% | ||
| Q3 24 | — | -16.6% | ||
| Q2 24 | — | -28.7% | ||
| Q1 24 | — | -31.7% |
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 5.1% | ||
| Q2 25 | — | 7.3% | ||
| Q1 25 | — | 19.3% | ||
| Q4 24 | — | 7.9% | ||
| Q3 24 | — | 16.5% | ||
| Q2 24 | — | 17.4% | ||
| Q1 24 | — | 35.8% |
| Q4 25 | 3.39× | — | ||
| Q3 25 | 1.91× | — | ||
| Q2 25 | 3.49× | — | ||
| Q1 25 | -5.66× | — | ||
| Q4 24 | 4.36× | — | ||
| Q3 24 | 4.72× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -31.03× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
WEST
| Coffee And Tea | $202.6M | 60% |
| Flavors Extracts And Ingredients | $69.6M | 21% |
| Sustainable Sourcing And Traceability Segments | $66.9M | 20% |
